NCT00747344 - A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

March 31, 2010

Conditions

Psoriasis

Interventions

DRUG

Placebo - Controlled Period (CP)

Placebo, Weeks 0-12

DRUG

Ustekinumab 45 mg - CP

Ustekinumab 45 mg, Weeks 0-12

DRUG

Placebo to ustekinumab 45 mg - after CP

Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16

DRUG

Ustekinumab 45 mg - after CP

Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16

Trial Locations (5)

Anyang

Seoul

Changhua

Kaohsiung County

Taipei